Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Cognitive Decline Can Start 20 Years Before Symptoms Appear. The FDA Just Cleared a ...

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

opportunities

◆ Sectors

Digital Health

◆ Geography

United States

◆ Source

Read at inc.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

The FDA cleared C2N Diagnostics' PrecivityAD2 blood test for Alzheimer's detection in adults as young as 40, enabling diagnosis up to 20 years before symptoms appear.

This Wire brief sits within Fusion42's coverage of Digital Health, and 4 sources have reported it between 20 Aug 2026 and 21 Aug 2026.

◆ ◆ The Wire takeaway

You can now build services based on earlier Alzheimer's detection with FDA backing, opening access to younger patient populations and shifting care timelines earlier.

◆ Coverage

4 sources · first reported 20 Aug 2026 · latest 21 Aug 2026

◆ Related on Wire

◆ Topics

Digital Healthalzheimersblood-testearly-detectionFDA-clearancediagnostics